Skip to main content

As many as 24 Canadians, including one who died, suffered from a severe allergic reaction after receiving the H1N1 pandemic vaccine.

But health officials stressed Wednesday that the rate of anaphylaxis appears to be low: 0.32 per 100,000 doses. Anaphylaxis is a severe allergic reaction that can be characterized by respiratory distress, swelling of the lips, eyelids, throat or tongue, and low blood pressure, and can be life-threatening.

"As we move through this, we will have numbers or rates that are higher and lower. But at the end of the day, it is the overall safety of the vaccine which is really clear and we have a great deal of confidence in [it]" said David Butler-Jones, Canada's chief public health officer.

Story continues below advertisement

All vaccines can induce anaphylaxis but do so at very low rates. The majority of side-effects are minor reactions, such as soreness at the injection site.

The elderly person who died after receiving the H1N1 shot had other health problems, so officials are still investigating the cause of death.

Federal officials said Wednesday that influenza activity appears to be levelling off in some parts of the country, like British Columbia, although it is still as much as seven times higher across the country than normal for this time of year.

Roughly 10 per cent of Canadians have been infected, and another 25 per cent have been immunized. That means the vast majority of people still risk serious infection and possibly death if they don't get the H1N1 shot, Dr. Butler-Jones said.

While many experts agree that the second wave of the virus appears to be peaking, there is talk in some circles of a potential third wave or the virus reappearing next fall. More than 15 million doses of vaccine have been distributed across the country, as flu clinics open their doors to healthy people.

"I'm really concerned about the Christmas period when we do share so many things. Good things usually. But unfortunately also infectious diseases," Dr. Butler-Jones said.

He added: "The more that are immunized, the harder it is for this virus to spread."

Report an error
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter